article thumbnail

Competition is on the horizon for costly narcolepsy treatments

pharmaphorum

But increased competition is on the horizon. Competition starts to heat up. In a case filed in California in 2021, Molina Healthcare claimed Jazz Pharmaceuticals engaged in a “comprehensive anticompetitive scheme to suppress generic competition for Xyrem,” abused the REMS program, and “engaged in sham patent litigation.”.

article thumbnail

FDA approves first Stelara biosimilar, Wezlana

European Pharmaceutical Review

Sustainable biosimilar competition in Europe: can it be achieved? Stelara biosimilars in the US market The first Stelara biosimilars are expected to enter the US market in 2025. “We He added that the approval of Wezlana “could have a meaningful impact for patients managing their disease.”

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Eli Lilly achieving significant gains in obesity results

Pharmaceutical Technology

Mounjaro’s approval for obesity, particularly in the US and EU markets, means the drug is entering a significantly large market where it will have direct competition from Novo Nordisk’s Wegovy (semaglutide), which is currently the leading glucagon-like peptide-1 (GLP-1) therapy approved for obesity by both the FDA and EMA.

Leads 98
article thumbnail

Consequences of the First 10 Drugs Selected for Medicare’s Negotiation Program

PM360

They do not have biosimilar or generic competition available in the market. Additionally, highly competitive classes, such as rapid-acting insulin and immunologics are included on the selected drug list. They do not qualify for any exemption (e.g., for orphan products or plasma therapies).

article thumbnail

Tips to Boost B2B Medical Sales

Scott’s Directories

There are a few ways to help boost these sales and remain competitive. billion by the end of 2025, from $196.3 Having a competitive edge is essential in the growing healthcare market. When dealing with medical sales, utilizing a Canadian Doctors Directory is a sure way to generate new clients. billion in 2017”.

article thumbnail

The osteoarthritis market is expected to increase to $3.8bn in 2031

Pharmaceutical Technology

Two categories of novel therapies stand out: cell therapies and therapies with novel MOAs, with new products in each category being forecast to launch between 2023 and 2025. However, the late-stage pipeline is seeing new companies enter the space, with intense competition for patient share driving innovation.

article thumbnail

Chinese manufacturers’ transition to innovative pharma requires more investment

Pharmaceutical Technology

China will continue to take steps towards becoming as competitive in high-value innovative pharma as it is in the generics industry, with The Wall Street Journal reporting Chinese biotechs raised $1.6tn through 568 venture financings last year, up from $11bn in 418 deals in 2020.